The Future Of Filling: Addressing The Challenges Of Late-Stage Manufacturing With Aseptic Filling Solutions

With a goal of developing standardized aseptic filling technologies that are optimal for today’s advanced therapies, Cytiva is seeking to define what “optimal” really means. To gain insights, the current landscape of filling and late-stage manufacturing was examined to identify both risks and opportunities for improvement. 78 professionals were consulted from top biopharmaceutical, biotechnology, contract manufacturing, and cell and gene therapy or personalized medicine companies to better understand the limitations, needs, and risks they face in producing next-generation treatments. Keep reading to hear what they said about the challenges of late-stage manufacturing.